Radiopharm Theranostics Ltd ADRRAD
Price$1.48

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value not published yet, our data-reliability standards weren't met; method estimates belowbased on filings through 30 Jun 2025
Market Price $1.48Price as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: -7.9%/yr (balance of the path).-5.5% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 6-5.7%Yr 7-3.5%Yr 8-1.4%Yr 90.8%Yr 103.0%
-7.9% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 8.7%
Volatility vs market (adjusted beta)0.83

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetRadiopharm Theranostics Ltd ADRRADHealth Care
Valuation
P/E—
P/S6.6×
P/B80.1×
EV / Revenue3.8×
EV / EBITDA—
Profitability
Gross margin7.4%
Operating margin-1,050.6%
Net margin-1,055.3%
FCF margin-1,009.8%
Returns
ROE-89.4%
ROA-44.3%
ROIC—
Growth
Revenue growth (YoY)0.0%
5-yr fwd EPS growth-5.5%
Financial strength
Debt / Equity0.00×
Current ratio2.67×
Altman Z-Score—
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.